(Q37622887)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Haemophilus influenzae

object named as

Haemophilus influenzae

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Lode Schuerman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

1 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1479-1500

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

Pneumococcal vaccination in developing countries.

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

The preventable burden of pneumococcal disease in the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Prevalence of pneumococcal bacteremia among children <36 months of age presenting with moderate fever to pediatric emergency rooms of the Metropolitan Region (Santiago), Chile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Incidence of clinically significant bacteraemia in children who present to hospital in Kenya: community-based observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Bacteremia among children admitted to a rural hospital in Kenya.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Prospects for a vaccine against otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Clinical course, complications and sequelae of acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Impact of the pneumococcal conjugate vaccine on otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Otitis media in Australian Aboriginal children: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Epidemiology and etiology of childhood pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Role of nontypeable Haemophilus influenzae in pediatric respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Penicillin resistance and serotyping of Streptococcus pneumoniae in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Epidemiological differences among pneumococcal serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Complicated parapneumonic effusion in Belgian children: increased occurrence before routine pneumococcal vaccine implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Pediatric parapneumonic empyema, Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from The Gambia: expansion of ST217 hypervirulent clonal complex in West Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Surveillance for invasive Streptococcus pneumoniae disease among hospitalized children in Bangladesh: antimicrobial susceptibility and serotype distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Capsular Types and Antibiotic Susceptibility of Invasive Streptococcus pneumoniae Among Children in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Potential alterations in immunogenicity by combining or simultaneously administering vaccine components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Correlates of immunity for pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Evolution of conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Maternal pneumococcal conjugate immunization protects infant chinchillas in the pneumococcal otitis media model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Chinchilla as a robust, reproducible and polymicrobial model of otitis media and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Changes in frequency and pathogens causing acute otitis media in 1995-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

New vaccines against otitis media: projected benefits and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Pneumonia associated with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

The Bill & Melinda Gates Foundation's grant-making programme for global health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.113

21 January 2018

Identifiers

DOI

10.1586/ERV.09.113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863240%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference